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Mycophenolate Mofetil Therapeutic Drug Monitoring: Combined Multi-
linear Regression and Bayesian Limited Sampling Area Under the Curve
versus Standard Care
Abstract
Therapeutic drug monitoring (TDM) of mycophenolate mofetil (MMF) has been investigated using multiple
linear regression (MLR) and bayesian pharmacokinetics (BAY) independently. We hypothesize that
performing TDM using simultaneous MLR and BAY for guidance in MMF dose selection will decrease acute
rejection and risk of toxicity. Twenty-nine renal transplant (RT) patients were prospectively enrolled into a
study of CellCept® (MMF, Roche), having their mycophenolic acid (MPA) levels monitored and dose
adjusted to achieve target area under the curve (AUC) level of 45 mg.hr/L (range 40 – 50 mg.hr/L). This
cohort is compared to 28 control patients prescribed standard of care, fixed dose MMF. MPA monitoring is
associated with a non-significant decrease rate of acute rejection (AR) by 3 months. Increased rates of BK
polyoma virus (BK) infection were observed by 3 months. The high frequency of MMF dose decreases on day
30 and 60 is consistent with literature that MPA AUC increases with time.
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Mycophenolate Mofetil Therapeutic Drug Monitoring:  Combined Multi-linear Regression and 
Bayesian Limited Sampling Area Under the Curve versus Standard Care
Ian C. Doyle1, Ahmed Zikri2, William M. Bennett3, Leslie M. Shaw4, Michal J. Figurski4
1Pacific University Oregon School of Pharmacy;  2Department of Pharmacy, Legacy Good Samaritan Hospital;  3Transplant Services, 
Legacy Good Samaritan Hospital,  4Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center
Abstract
Therapeutic drug monitoring (TDM) of mycophenolate mofetil (MMF) has been 
investigated using multiple linear regression (MLR) and bayesian pharmacokinetics 
(BAY) independently.  We hypothesize that performing TDM using simultaneous 
MLR and BAY for guidance in MMF dose selection will decrease acute rejection and 
risk of toxicity. Twenty-nine renal transplant (RT) patients were prospectively 
enrolled into a study of CellCept® (MMF, Roche), having their mycophenolic acid 
(MPA) levels monitored and dose adjusted to achieve target area under the curve 
(AUC) level of 45 mg.hr/L (range 40 – 50 mg.hr/L).  This cohort is compared to 28 
control patients prescribed standard of care, fixed dose MMF.  MPA monitoring is 
associated with a non-significant decrease rate of acute rejection (AR) by 3 months.  
Increased rates of BK polyoma virus (BK) infection were observed by 3 months.  
The high frequency of MMF dose decreases on day 30 and 60 is consistent with 
literature that MPA AUC increases with time.
Introduction
Mycophenolate mofetil is an immunosuppressant medication used to prevent 
rejection in kidney transplantation. The standard dose of MMF is 1000 mg twice 
daily.  MMF undergoes enterohepatic recirculation, making it difficult to conduct 
TDM using peak and/or trough drug levels alone.  Recent large-scale studies 
demonstrate that MMF TDM via measuring AUC may decrease risk of rejection as 
Results Discussion
MMF dose adjustment evaluation:
•Use of a narrow therapeutic index of 40-50 mg.hr/L may be too difficult to achieve, 
and a larger range may be indicated.  Fifteen MPA levels during the course of the study 
indicated a dose change per protocol, but these were not completed as either the level 
was in the range of 30 to 60 mg.hr/L, and/or the incremental change of 250 mg per dose 
would have resulted in a level outside of range on the opposite end of the spectrum.
• The low rate of in-range AUC values on day 30 may indicate that more frequent AUC 
monitoring  is needed between day 7 and day 30.  Eight (31%) of the day 7 AUC levels 
prompted MMF decreases; 1 change was associated with a subtherapeutic AUC, while 
6 patients remained supratherapeutic on day 30.  Two of 4 off-protocol dose changes 
(dose decreases for adverse effects without verification of AUC) contributed to AUC < 
40 on day 30.
Outcomes:
• GI adverse effects were only measured on the days of AUC testing.  Patients 
experienced adverse effects between testing days, but this data was not uniformly 
recorded and cannot be correlated to MPA  levels.
• A significant decrease in WBC correlates to higher MMF doses utilized at day 7 in 
the TDM group.  Patient groups appear to be evenly controlled for induction therapy, so 
this should not have influenced differences in leukopenia.
• There may be a higher incidence of BK viruria associated with TDM.  MMF doses 
Groups Comparison TDM Fixed dose
Number enrolled
(withdrew or excluded for complications)
29 (5) 30 (2)
Men 14 12
Mean age (years) 56 59
Mean BMI (kg/m2) 27 28
Deceased donor 17 22
HLA mismatch: 0-1 / 2-4 / 5-6 2 / 14 / 10 2 / 11 / 14
PRA = 0% 22 23
Induction therapy:
Basiliximab / rATG ≤ 3mg/kg / rATG ≥ 3.1 mg/kg
2 / 25 / 2 2 / 23 / 4
Initial CNI = FK 22 21
TDM Fixed dose








Low CNI level on AUC day (FK < 4, CSA < 100) 9/26 5/24 6/24
10/
1/26 1/26 NS*
well as toxicity.  AUC is estimated via limited sampling strategy using MLR or BAY 
pharmacokinetics.  In this study, we use concomitant MLR and BAY to estimate 
MPA AUC, utilizing a less frequent monitoring schedule than previous studies.  We 
compare the therapeutic outcomes of these RT recipients to a concurrent fixed dose 
MMF cohort.
• NA = not available or not applicable
• NS = not significant, per logistic or linear regression, except (*) per Wilcoxan rank sum
• Patient lab values and outcomes data are included in result evaluation until time of withdraw 
from study.  AR results are reported using per-protocol analysis.
• Six month AR for TDM patients not controlled for MMF manufacturer.
• Six month AR not controlled for MMF dose changes made by primary nephrologist.
• TDM patient withdrawals by 3 months: insurance (2), GI intolerance (1) , Vascular access (1), 
Thrombosis of graft day nine (1).
• Control patient exclusions:  Thrombosis of graft (1), Loss to follow up (1)
Conclusions
• Evidenced by the low rate of in-range AUC values on day 30, more frequent AUC 
monitoring might be indicated during the first month post-transplant.
• The large proportion of MMF dose decreases on day 30 & 60 is consistent with 
literature that MPA AUC increases with time.
• Leukopenia may be associated with MMF TDM.
• Many patients can have their MMF dose decreased without increasing risk of AR.
• MMF TDM is associated with a non-significant decreased rate of AR at 3 months.
• Decreased rates of AR might be offset by increased rates of BK infection.
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averaged slightly higher in the TDM group at day 7 (possible overimmunsuppression), 
but lower at days 30 & 60.  Three of 4 patients with viruria, also developed viremia.
• TDM is associated with a non-significant decrease in AR at both 8 weeks and 3 
months.  Power to detect differences between groups  was not set a priori, and therefore 
this result may reflect a Type II error.
• There is no association between the use of TDM within the first 3 months and the 
incidence of rejection at 6 months.   Patient care is returned to the referring nephrologist
at 3 months, and medication protocol cannot be controlled.  Eight of 22 TDM patients’ 
MMF dose was decreased in the period between 3 and 6 months.  Two of these patients 
had biopsy proven rejection at 6 months.
• The average dose of MMF for TDM patients at day 60 is 113 mg lower than that of 
the fixed dose cohort.  Incidence ratios of subtherapeutic FK and CSA levels were 
greater on days 30 & 60 in the TDM group.  Lower doses of MMF may be used without 
increasing risk of AR, potentially decreasing patient costs and adverse drug effects.
Methods
This study received approval from the Legacy Health System IRB.  During the 
period of May 2009 to January 2010, 29 non-randomized RT patients were 
prospectively enrolled.  MMF was initiated at the time of renal transplant.   Patients 
concomitantly received tapering doses of prednisone, and either tacrolimus (FK), 
cyclosporine (CSA), or rapamune.
• Initial MMF dose:  1000 mg BID with FK, and 1500 mg BID with CSA.
• AUC samples were drawn on days 7, 30, and 60 post-transplantation.
• Limited sampling MPA levels were drawn at 0, 40, and 240 minutes, and at 0, 40, 
and 120 minutes for FK and CSA patients, respectively. 
• AUC was determined by averaging the results of two AUC methods:  MLR (using 
R 2.9.7) and Bayesian kinetics (using NONMEM).
• MMF doses were adjusted using MPA AUC results, in conjunction with the patient 
evaluation of the attending transplant nephrologist.
• Target MPA AUC level = 45 mg.hr/L (range 40 – 50 mg.hr/L). 
• MMF dose adjusted using 250 mg capsule increments, forecasting degree of  
change using linear kinetics.
• Patients were monitored for side effects on the AUC sampling days 7, 30, and 60.
• Surveillance biopsies were performed, unless clinically contraindicated, at 6-8 
weeks and 6 months post RT.
• Exclusions for study group:  Age < 18 or >70, BMI > 40, and pregnancy.
Fixed-dose MMF patients were assessed via retrospective chart review (RT 4/09 to 
11/09), and were not controlled for MMF manufacturer, or for age > 70.
28
Mean MMF (mg), after dose adjustment 1010 844 714 964 894 827
% within goal AUC 40 - 50 42 4 13 NA - -
% within AUC 30 - 60 65 38 58 NA - -
% (#) Dose changes based on AUC 50 (13) 67 (16) 46 (11) NA - -
% (#) Dose increases 19 (5) 13 (3) 13 (3) 0 0 0
% (#) Dose decreases 31 (8) 54 (13) 33 (8) 0 2 1
# times dose not changed when AUC was < 40 2 3 5 NA - -
# times dose not changed when AUC was > 50 0 4 5 NA - -
# dose changes occurring between visit days 
secondary to MMF side effects
0 4 4 0 7 4
WBC x103/mm3 (mean) 8.641 5.66 5.5 111 6.49 5.7 10.02
Hemoglobin g/dL (mean) 11 11.8 12.9 10.7 11 11.8 NS
GI intolerance (documented on AUC day) 3/26 2/24 2/24 2/27 3/26 1/26 NS
Long-term outcomes 8 wk 3 mo 6 mo 8 wk 3 mo 6 mo p
Acute Rejection
(BPAR or clinical; cumulative by time point)
3/24 4/24 7/22 7/27 7/26 9/25 NS
BK viruria , cumulative NA 4/24 NA NA 2/26 NA NS
BK viremia , cumulative NA 3/24 NA NA 1/26 NA NS
